11:49Novo Nordisk's Wegovy could reduce heart risks by 20%
From the creator
According to a new trial study, Novo Nordisk's (NVO) weight loss drug Wegovy may have the added benefit of cutting down risks tied to cardiovascular complications by at least 20%. Yahoo Finance Live monitors how Novo Nordisk's stock is reacting to this news in pre-market trading and analyzes how food brands may be planning to respond to the rise in GLP-1 drugs. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Subscribe to Yahoo Finance: https://yhoo.it/2fGu5Bb #youtube #Wegovy #stockmarket About Yahoo Finance: At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Yahoo Finance Plus: With a subscription to Yahoo Finance Plus get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades with advanced portfolio insights, fundamental analysis, enhanced charting, and more. To learn more about Yahoo Finance Plus please visit: https://yhoo.it/33jXYBp Connect with Yahoo Finance: Get the latest news: https://yhoo.it/2fGu5Bb Find Yahoo Finance on Facebook: http://bit.ly/2A9u5Zq Follow Yahoo Finance on Twitter: http://bit.ly/2LMgloP Follow Yahoo Finance on Instagram: http://bit.ly/2LOpNYz Follow Yahoo Finance Premium on Twitter: https://bit.ly/3hhcnmV
Published 2023-11-13 · Watch on YouTube ↗
Availability and playback restrictions are controlled by the original channel.





